Navigation Links
Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings
Date:5/20/2009

BERGISCH GLADBACH, Germany, May 20 /PRNewswire/ -- Miltenyi Biotec announces the worldwide and exclusive release of Myelin Removal Beads. Myelin is a specialized membrane which ensheathes and insulates axons in the peripheral and central nervous system. During preparation of single-cell suspensions, myelin membrane fragments represent the major contaminant. "When dissociating adult neural tissue, usually less than 5 percent of the cell suspension consists of cells. The rest corresponds to cell debris", explains Dr. Rebecca Biloune, Product Manager for Neural Research Products at Miltenyi Biotec. "Removal of myelin leads to higher purity and recovery of target cells."

The novel product is suited for myelin removal from single-cell suspensions obtained from human, mouse, and rat tissues and is especially recommended prior to cell separations and cell stainings with Anti-Prominin-1 , CD133, Anti-PSA-NCAM, Anti-A2B5, or CD11b (microglia) MicroBeads and fluorochrome-conjugated antibodies, respectively.

"The beads work seamlessly with other MACS Technology products", adds Dr. Biloune. "Contaminating myelin fragments can be depleted either by manual protocols or by automated magnetic separations with the autoMACS(TM) Separator or the MACSQuant(TM) Analyzer." Myelin Removal Beads are exclusively available from Miltenyi Biotec. Detailed information is available at http://www.myelinremoval.com.

About Miltenyi Biotec

The company is one of the largest and most successful biotechnology companies in Germany. More than 1,100 employees worldwide develop, produce and sell products for biomedical research and clinical applications. The renowned MACS Technology for magnetic separation of cells has become a standard technology in research laboratories worldwide.

    Contact
    Prof. Dr. Uwe Heinlein, Corporate Communications, Miltenyi Biotec GmbH
    Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany
    Phone +49-2204-8306-0, e-mail uweh@miltenyibiotec.de


   http://www.miltenyibiotec.com

'/>"/>
SOURCE Miltenyi Biotec GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
2. Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments
3. September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging
4. Gallbladder Removal Through Vagina Offers Minimally Invasive Alternative
5. AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. Neuralstem Announces Issuance of Core Technology Patent in Europe
8. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
9. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
10. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
11. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... May 26, 2016   Change Healthcare ... analytics, network solutions and technology-enabled services designed ... entered into a strategic channel partnership with ... software solutions and revenue cycle management services ... and rehabilitation clinics to optimize revenue, operational ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, 2016 ... ; Frankfurt Prime Standard: QIA) today announced that the company ... Diagnostics GmbH to develop and commercialize predictive assays in oncology. ... as a marker to predict effectiveness of anthracycline treatment in ... "We are pleased to partner with Therawis, which developed the ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... Mediaplanet to help educate the many who are unaware of the plight of ... aphasia will run within the “Stroke Awareness” campaign. , The link between stroke ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
(Date:5/26/2016)... ... , ... Despite last week’s media reports hinting at a June rate hike ... March 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic ... Federal Open Market Committee (FOMC) dot charts are of interest to the press for ...
Breaking Medicine News(10 mins):